Doxazosin in combination with atenolol in essential hypertension : a double-blind placebo-controlled multicentre trial
Doxazosin (mean dose 11 mg) given once daily in combination with 100 mg atenolol (n = 44) was compared with placebo and atenolol (n = 43) in a double-blind, multicenter study in patients with mild to moderate essential hypertension. In the atenolol/doxazosin-treated group, standing blood pressure si...
Gespeichert in:
| Veröffentlicht in: | European journal of clinical pharmacology 1990-09, Vol.39 (3), p.299-300 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 300 |
|---|---|
| container_issue | 3 |
| container_start_page | 299 |
| container_title | European journal of clinical pharmacology |
| container_volume | 39 |
| creator | SEARLE, M DATHAN, R DEAN, S CHRISTENSEN, C. C WESTHEIM, A |
| description | Doxazosin (mean dose 11 mg) given once daily in combination with 100 mg atenolol (n = 44) was compared with placebo and atenolol (n = 43) in a double-blind, multicenter study in patients with mild to moderate essential hypertension. In the atenolol/doxazosin-treated group, standing blood pressure significantly decreased by 17.0/12.3 mm Hg compared to 6.2/6.7 mm Hg in the atenolol/placebo group whereas supine blood pressure decreased by 13.2/9.8 mm Hg and 9.2/6.0 mm Hg, respectively in the two groups. Serum lipids did not change significantly in either group. The majority of side-effects reported were mild and transient. This study confirms that doxazosin may be safely combined with a beta-blocker. Doxazosin proved to be well tolerated and effective in patients with blood pressure refractory to atenolol alone. |
| doi_str_mv | 10.1007/BF00315116 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_80165884</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>80165884</sourcerecordid><originalsourceid>FETCH-LOGICAL-c227t-4a95027d4811cea598634d1ef686336d1f0ab46570d591baf9fb22465b3930593</originalsourceid><addsrcrecordid>eNpFkM1LHTEUxUNRnq_aTfdCNnZRGL13kvlId_a1VkFwo-shyWQwJZO8Jpmq_evNw0eFC_dyzu-exSHkM8I5AnQX368AGDaI7QeyRs7qCoHjAVnv5KoVHRyRjyn9BsBGAFuRVY28EyDW5O-P8Cz_hWQ9LaPDrKyX2QZPn2x-pDIbH1xwO9OkZHy20tHHl62JxUk77huVdAyLcqZSzvqRbp3URoVKB59jcM6MdF5ctrp8R0NzLBEn5HCSLplP-31MHq5-3m-uq9u7Xzeby9tK13WXKy5FA3U38h5RG9mIvmV8RDO15WDtiBNIxdumg7ERqOQkJlXXRVBMMGgEOyZf3nK3MfxZTMrDbJM2zklvwpKGHrBt-p4X8OsbqGNIKZpp2EY7y_gyIAy7kof3kgt8uk9d1GzG_-i-1eKf7X2ZtHRTlF7b9J4oGK9bhuwVOl6EoQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>80165884</pqid></control><display><type>article</type><title>Doxazosin in combination with atenolol in essential hypertension : a double-blind placebo-controlled multicentre trial</title><source>MEDLINE</source><source>Springer Online Journals</source><creator>SEARLE, M ; DATHAN, R ; DEAN, S ; CHRISTENSEN, C. C ; WESTHEIM, A</creator><creatorcontrib>SEARLE, M ; DATHAN, R ; DEAN, S ; CHRISTENSEN, C. C ; WESTHEIM, A</creatorcontrib><description>Doxazosin (mean dose 11 mg) given once daily in combination with 100 mg atenolol (n = 44) was compared with placebo and atenolol (n = 43) in a double-blind, multicenter study in patients with mild to moderate essential hypertension. In the atenolol/doxazosin-treated group, standing blood pressure significantly decreased by 17.0/12.3 mm Hg compared to 6.2/6.7 mm Hg in the atenolol/placebo group whereas supine blood pressure decreased by 13.2/9.8 mm Hg and 9.2/6.0 mm Hg, respectively in the two groups. Serum lipids did not change significantly in either group. The majority of side-effects reported were mild and transient. This study confirms that doxazosin may be safely combined with a beta-blocker. Doxazosin proved to be well tolerated and effective in patients with blood pressure refractory to atenolol alone.</description><identifier>ISSN: 0031-6970</identifier><identifier>EISSN: 1432-1041</identifier><identifier>DOI: 10.1007/BF00315116</identifier><identifier>PMID: 2147909</identifier><language>eng</language><publisher>Heidelberg: Springer</publisher><subject>Adolescent ; Adult ; Aged ; Antihypertensive agents ; Antihypertensive Agents - administration & dosage ; Antihypertensive Agents - therapeutic use ; Atenolol - administration & dosage ; Atenolol - therapeutic use ; Biological and medical sciences ; Blood Pressure - drug effects ; Cardiovascular system ; Double-Blind Method ; Doxazosin ; Drug Therapy, Combination ; Humans ; Hypertension - drug therapy ; Medical sciences ; Middle Aged ; Pharmacology. Drug treatments ; Prazosin - administration & dosage ; Prazosin - analogs & derivatives ; Prazosin - therapeutic use</subject><ispartof>European journal of clinical pharmacology, 1990-09, Vol.39 (3), p.299-300</ispartof><rights>1991 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c227t-4a95027d4811cea598634d1ef686336d1f0ab46570d591baf9fb22465b3930593</citedby><cites>FETCH-LOGICAL-c227t-4a95027d4811cea598634d1ef686336d1f0ab46570d591baf9fb22465b3930593</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=19342631$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/2147909$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>SEARLE, M</creatorcontrib><creatorcontrib>DATHAN, R</creatorcontrib><creatorcontrib>DEAN, S</creatorcontrib><creatorcontrib>CHRISTENSEN, C. C</creatorcontrib><creatorcontrib>WESTHEIM, A</creatorcontrib><title>Doxazosin in combination with atenolol in essential hypertension : a double-blind placebo-controlled multicentre trial</title><title>European journal of clinical pharmacology</title><addtitle>Eur J Clin Pharmacol</addtitle><description>Doxazosin (mean dose 11 mg) given once daily in combination with 100 mg atenolol (n = 44) was compared with placebo and atenolol (n = 43) in a double-blind, multicenter study in patients with mild to moderate essential hypertension. In the atenolol/doxazosin-treated group, standing blood pressure significantly decreased by 17.0/12.3 mm Hg compared to 6.2/6.7 mm Hg in the atenolol/placebo group whereas supine blood pressure decreased by 13.2/9.8 mm Hg and 9.2/6.0 mm Hg, respectively in the two groups. Serum lipids did not change significantly in either group. The majority of side-effects reported were mild and transient. This study confirms that doxazosin may be safely combined with a beta-blocker. Doxazosin proved to be well tolerated and effective in patients with blood pressure refractory to atenolol alone.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Antihypertensive agents</subject><subject>Antihypertensive Agents - administration & dosage</subject><subject>Antihypertensive Agents - therapeutic use</subject><subject>Atenolol - administration & dosage</subject><subject>Atenolol - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Blood Pressure - drug effects</subject><subject>Cardiovascular system</subject><subject>Double-Blind Method</subject><subject>Doxazosin</subject><subject>Drug Therapy, Combination</subject><subject>Humans</subject><subject>Hypertension - drug therapy</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Pharmacology. Drug treatments</subject><subject>Prazosin - administration & dosage</subject><subject>Prazosin - analogs & derivatives</subject><subject>Prazosin - therapeutic use</subject><issn>0031-6970</issn><issn>1432-1041</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1990</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkM1LHTEUxUNRnq_aTfdCNnZRGL13kvlId_a1VkFwo-shyWQwJZO8Jpmq_evNw0eFC_dyzu-exSHkM8I5AnQX368AGDaI7QeyRs7qCoHjAVnv5KoVHRyRjyn9BsBGAFuRVY28EyDW5O-P8Cz_hWQ9LaPDrKyX2QZPn2x-pDIbH1xwO9OkZHy20tHHl62JxUk77huVdAyLcqZSzvqRbp3URoVKB59jcM6MdF5ctrp8R0NzLBEn5HCSLplP-31MHq5-3m-uq9u7Xzeby9tK13WXKy5FA3U38h5RG9mIvmV8RDO15WDtiBNIxdumg7ERqOQkJlXXRVBMMGgEOyZf3nK3MfxZTMrDbJM2zklvwpKGHrBt-p4X8OsbqGNIKZpp2EY7y_gyIAy7kof3kgt8uk9d1GzG_-i-1eKf7X2ZtHRTlF7b9J4oGK9bhuwVOl6EoQ</recordid><startdate>199009</startdate><enddate>199009</enddate><creator>SEARLE, M</creator><creator>DATHAN, R</creator><creator>DEAN, S</creator><creator>CHRISTENSEN, C. C</creator><creator>WESTHEIM, A</creator><general>Springer</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>199009</creationdate><title>Doxazosin in combination with atenolol in essential hypertension : a double-blind placebo-controlled multicentre trial</title><author>SEARLE, M ; DATHAN, R ; DEAN, S ; CHRISTENSEN, C. C ; WESTHEIM, A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c227t-4a95027d4811cea598634d1ef686336d1f0ab46570d591baf9fb22465b3930593</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1990</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Antihypertensive agents</topic><topic>Antihypertensive Agents - administration & dosage</topic><topic>Antihypertensive Agents - therapeutic use</topic><topic>Atenolol - administration & dosage</topic><topic>Atenolol - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Blood Pressure - drug effects</topic><topic>Cardiovascular system</topic><topic>Double-Blind Method</topic><topic>Doxazosin</topic><topic>Drug Therapy, Combination</topic><topic>Humans</topic><topic>Hypertension - drug therapy</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Pharmacology. Drug treatments</topic><topic>Prazosin - administration & dosage</topic><topic>Prazosin - analogs & derivatives</topic><topic>Prazosin - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>SEARLE, M</creatorcontrib><creatorcontrib>DATHAN, R</creatorcontrib><creatorcontrib>DEAN, S</creatorcontrib><creatorcontrib>CHRISTENSEN, C. C</creatorcontrib><creatorcontrib>WESTHEIM, A</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of clinical pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>SEARLE, M</au><au>DATHAN, R</au><au>DEAN, S</au><au>CHRISTENSEN, C. C</au><au>WESTHEIM, A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Doxazosin in combination with atenolol in essential hypertension : a double-blind placebo-controlled multicentre trial</atitle><jtitle>European journal of clinical pharmacology</jtitle><addtitle>Eur J Clin Pharmacol</addtitle><date>1990-09</date><risdate>1990</risdate><volume>39</volume><issue>3</issue><spage>299</spage><epage>300</epage><pages>299-300</pages><issn>0031-6970</issn><eissn>1432-1041</eissn><abstract>Doxazosin (mean dose 11 mg) given once daily in combination with 100 mg atenolol (n = 44) was compared with placebo and atenolol (n = 43) in a double-blind, multicenter study in patients with mild to moderate essential hypertension. In the atenolol/doxazosin-treated group, standing blood pressure significantly decreased by 17.0/12.3 mm Hg compared to 6.2/6.7 mm Hg in the atenolol/placebo group whereas supine blood pressure decreased by 13.2/9.8 mm Hg and 9.2/6.0 mm Hg, respectively in the two groups. Serum lipids did not change significantly in either group. The majority of side-effects reported were mild and transient. This study confirms that doxazosin may be safely combined with a beta-blocker. Doxazosin proved to be well tolerated and effective in patients with blood pressure refractory to atenolol alone.</abstract><cop>Heidelberg</cop><cop>Berlin</cop><pub>Springer</pub><pmid>2147909</pmid><doi>10.1007/BF00315116</doi><tpages>2</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0031-6970 |
| ispartof | European journal of clinical pharmacology, 1990-09, Vol.39 (3), p.299-300 |
| issn | 0031-6970 1432-1041 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_80165884 |
| source | MEDLINE; Springer Online Journals |
| subjects | Adolescent Adult Aged Antihypertensive agents Antihypertensive Agents - administration & dosage Antihypertensive Agents - therapeutic use Atenolol - administration & dosage Atenolol - therapeutic use Biological and medical sciences Blood Pressure - drug effects Cardiovascular system Double-Blind Method Doxazosin Drug Therapy, Combination Humans Hypertension - drug therapy Medical sciences Middle Aged Pharmacology. Drug treatments Prazosin - administration & dosage Prazosin - analogs & derivatives Prazosin - therapeutic use |
| title | Doxazosin in combination with atenolol in essential hypertension : a double-blind placebo-controlled multicentre trial |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T16%3A02%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Doxazosin%20in%20combination%20with%20atenolol%20in%20essential%20hypertension%20:%20a%20double-blind%20placebo-controlled%20multicentre%20trial&rft.jtitle=European%20journal%20of%20clinical%20pharmacology&rft.au=SEARLE,%20M&rft.date=1990-09&rft.volume=39&rft.issue=3&rft.spage=299&rft.epage=300&rft.pages=299-300&rft.issn=0031-6970&rft.eissn=1432-1041&rft_id=info:doi/10.1007/BF00315116&rft_dat=%3Cproquest_cross%3E80165884%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=80165884&rft_id=info:pmid/2147909&rfr_iscdi=true |